A Dose Escalation of Zarnestra (R115777) Combined With Velcade (PS-341) in Patients With Relapsed Multiple Myeloma.

Trial Profile

A Dose Escalation of Zarnestra (R115777) Combined With Velcade (PS-341) in Patients With Relapsed Multiple Myeloma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2011

At a glance

  • Drugs Bortezomib; Tipifarnib
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top